FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147695034> ?p ?o ?g. }

• W3147695034 abstract "495 Hyperactive NRAS downstream signaling induces specific transcriptome changes eesiRNA based identification of new therapeutic targets in NRAS mutant melanoma identifies the noncoding RNA 7SL as a major proliferation enhancer I Vujic, M Vujic, M Sanlorenzo, C Posch, A Preschitz, R Esteve-Puig, K Lai, W Ho, K Rappersberger and S Ortiz-Urda 1 Dermatology, KA Rudolfstiftung, Vienna, Austria and 2 Dermatology, University of California, San Francisco, San Francisco, CA Benign naevi and malignant melanomas both can have oncogenic mutations in the NRAS gene but naevi only rarely progress to cancer. Such NRAS mutations should lead to specific transcriptome changes. The knowledge of these changes can A) identify new therapeutic targets and B) explain why some naevi have NRAS mutations but stay benign. Here, we introduce NRAS(Q61) mutant plasmids in a pool of human melanocytes to overactivate NRAS downstream pathways. We perform deep RNASeq and compare transcriptome changes in melanocytes with and without NRAS mutation. We list differentially expressed coding and noncoding transcripts by filtering our results with transcriptomes from 2 NRAS mutant melanoma cell lines and 89 NRAS mutant patient tumors. Next we use esiRNA (Endoribonuclease-prepared siRNA) libraries to knock down these transcripts and perform proliferation assays to identify potential targets. For most promising candidates we perform further siRNA knockdowns, cell based assays and take a closer look at their mechanistics. Our approach identified 237 transcripts, of which 2 coding and 6 noncoding transcripts played an important role in the proliferation of NRAS mutant melanoma. The knockdown of each of these transcripts led to cell proliferation decreases of 30-60%. We focused on the noncoding RNA RN7SL1 and identified its up-stream regulation (MAPK pathway) and its downstream effectors (p53). In conclusion, we identify new therapeutic targets which might be used in the battle against NRAS mutant melanoma. 496 Radiation therapy in melanoma patients with poor clinical characteristics e a collaborative experience with 107 patients C Posch, C Steffal, A Haider, B Flechl, T Kann, F Weihsengruber, A Schratter-Sehn and K Rappersberger 1 Dermatology, The Rudolfstiftung Hospital, Vienna, Austria and 2 Radiooncology, Kaiser-Franz-JOsef Hospital, Vienna, Austria Radiation therapy (RTX) is an important part of melanoma management. Even though it is effective for local disease control, the lack of improved overall survival often dampens enthusiasm for this therapeutic modality. We describe our collaborative experience treating 107 stage III and stage IV melanoma patients managed at a dermatology department and a radio-oncology center using therapeutic or adjuvant radiation. Our cohort comprised a subset of melanoma patients with unfavorable clinical characteristics (median Breslow thickness: 2.8mm (range 0.5-18mm); clinical stage at diagnosis: III+IV n1⁄495). The median age at diagnosis was 60.3 (13.6-90.0) years the median age at start of irradiation was 66.2 (20.691.5) years. The axillary area was the most frequent anatomical site for irradiation (n1⁄430) followed by bone irradiation (n1⁄420). The majority of patients received additional systemic therapy including immunotherapy (n1⁄460), chemotherapy (n1⁄450) and targeted therapy (n1⁄47). Average overall survival (OS) was calculated with 57.3 (SD 52.1) months. Average overall survival after RTX (OSaRTX) was 17.1 (SD 18.7) months. Loco-regional recurrence (LRR) of melanoma was observed in 17 irradiated areas. No difference in OS or OSaRTX and locoregional recurrence was found: OS without LRR 57.6 (SEM 5.7) years; OS with LRR 55.6 (SEM 9.2) years; OSaRTX without LRR 16.2 (SEM 1.8) years, OSaRTX with LRR 20.6 (SEM 3.8) years (all p>0.05). LDH serum levels did not correlate with local recurrence (r1⁄40.07). Subgroup analyses revealed that OSaRTX for axillary irradiation was 26.3 (SD 24.6) months. RTX was well tolerated with the majority of acute adverse events being grade 1 (CTCAE v4.02). 11 patients experienced late irradiation adverse effects (all grade 1; RTOG/EORTC score). From our data we conclude that RTX is a well-tolerated therapeutic modality with the potential for high local disease control, particularly in the axillary region." @default.
• W3147695034 created "2021-04-13" @default.
• W3147695034 creator A5000550639 @default.
• W3147695034 creator A5005385380 @default.
• W3147695034 creator A5007756094 @default.
• W3147695034 creator A5017408978 @default.
• W3147695034 creator A5042196465 @default.
• W3147695034 creator A5064097238 @default.
• W3147695034 creator A5066052761 @default.
• W3147695034 creator A5083160716 @default.
• W3147695034 creator A5086426562 @default.
• W3147695034 date "2016-01-01" @default.
• W3147695034 modified "2023-10-18" @default.
• W3147695034 title "500 Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma" @default.
• W3147695034 hasPublicationYear "2016" @default.
• W3147695034 type Work @default.
• W3147695034 sameAs 3147695034 @default.
• W3147695034 citedByCount "0" @default.
• W3147695034 crossrefType "journal-article" @default.
• W3147695034 hasAuthorship W3147695034A5000550639 @default.
• W3147695034 hasAuthorship W3147695034A5005385380 @default.
• W3147695034 hasAuthorship W3147695034A5007756094 @default.
• W3147695034 hasAuthorship W3147695034A5017408978 @default.
• W3147695034 hasAuthorship W3147695034A5042196465 @default.
• W3147695034 hasAuthorship W3147695034A5064097238 @default.
• W3147695034 hasAuthorship W3147695034A5066052761 @default.
• W3147695034 hasAuthorship W3147695034A5083160716 @default.
• W3147695034 hasAuthorship W3147695034A5086426562 @default.
• W3147695034 hasConcept C104317684 @default.
• W3147695034 hasConcept C143065580 @default.
• W3147695034 hasConcept C145059251 @default.
• W3147695034 hasConcept C150194340 @default.
• W3147695034 hasConcept C162317418 @default.
• W3147695034 hasConcept C173396325 @default.
• W3147695034 hasConcept C21790070 @default.
• W3147695034 hasConcept C2777658100 @default.
• W3147695034 hasConcept C2781187634 @default.
• W3147695034 hasConcept C501734568 @default.
• W3147695034 hasConcept C502942594 @default.
• W3147695034 hasConcept C54355233 @default.
• W3147695034 hasConcept C86803240 @default.
• W3147695034 hasConceptScore W3147695034C104317684 @default.
• W3147695034 hasConceptScore W3147695034C143065580 @default.
• W3147695034 hasConceptScore W3147695034C145059251 @default.
• W3147695034 hasConceptScore W3147695034C150194340 @default.
• W3147695034 hasConceptScore W3147695034C162317418 @default.
• W3147695034 hasConceptScore W3147695034C173396325 @default.
• W3147695034 hasConceptScore W3147695034C21790070 @default.
• W3147695034 hasConceptScore W3147695034C2777658100 @default.
• W3147695034 hasConceptScore W3147695034C2781187634 @default.
• W3147695034 hasConceptScore W3147695034C501734568 @default.
• W3147695034 hasConceptScore W3147695034C502942594 @default.
• W3147695034 hasConceptScore W3147695034C54355233 @default.
• W3147695034 hasConceptScore W3147695034C86803240 @default.
• W3147695034 hasLocation W31476950341 @default.
• W3147695034 hasOpenAccess W3147695034 @default.
• W3147695034 hasPrimaryLocation W31476950341 @default.
• W3147695034 hasRelatedWork W1482524425 @default.
• W3147695034 hasRelatedWork W1991144222 @default.
• W3147695034 hasRelatedWork W2037284094 @default.
• W3147695034 hasRelatedWork W2117788890 @default.
• W3147695034 hasRelatedWork W2138157385 @default.
• W3147695034 hasRelatedWork W2146577187 @default.
• W3147695034 hasRelatedWork W2473482236 @default.
• W3147695034 hasRelatedWork W2533625150 @default.
• W3147695034 hasRelatedWork W2591276289 @default.
• W3147695034 hasRelatedWork W2594897444 @default.
• W3147695034 hasRelatedWork W2603442965 @default.
• W3147695034 hasRelatedWork W2611416403 @default.
• W3147695034 hasRelatedWork W2745109354 @default.
• W3147695034 hasRelatedWork W2759520733 @default.
• W3147695034 hasRelatedWork W2897889923 @default.
• W3147695034 hasRelatedWork W2904200760 @default.
• W3147695034 hasRelatedWork W2978698550 @default.
• W3147695034 hasRelatedWork W3011070425 @default.
• W3147695034 hasRelatedWork W3039007149 @default.
• W3147695034 hasRelatedWork W3092722771 @default.
• W3147695034 isParatext "false" @default.
• W3147695034 isRetracted "false" @default.
• W3147695034 magId "3147695034" @default.
• W3147695034 workType "article" @default.